ELISA/assay

Human Fibrinogen beta ELISA Kit

MBS723818

48-Strip-Wells-(Comp

470 USD

ELISA Kit

Human Fibrinogen beta ELISA Kit

Fibrinogen beta

Human Fibrinogen b ELISA Kit

fibrinogen beta chain isoform 1 preproprotein; Fibrinogen beta chain; fibrinogen beta chain; fibrinogen, B beta polypeptide; epididymis secretory sperm binding protein Li 78p; fibrinogen beta chain

FGbeta

FGb

FGB; FGB; HEL-S-78p

FIBB_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of FG-?. No significant cross-reactivity or interference between FG-? and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between FG-? and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Assay Type: Competitive or Sandwich. Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Sensitivity: 1.0 ng/mL.

Intended Uses: This FG-? ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human FG-?. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cardiovascular

Principle of the assay: FG-? ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-FG-? antibody and an FG-?-HRP conjugate. The assay sample and buffer are incubated together with FG-?-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the FG-? concentration since FG-? from samples and FG-?-HRP conjugate compete for the anti-FG-? antibody binding site. Since the number of sites is limited, as more sites are occupied by FG-? from the sample, fewer sites are left to bind FG-?-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The FG-? concentration in each sample is interpolated from this standard curve.

70906435

NP_005132.2

NM_005141.4

55,928 Da

Blood Clotting Cascade Pathway (198840); Common Pathway (106060); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Extracellular Matrix Organization Pathway (576262); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); GRB2:SOS Provides Linkage To MAPK Signaling For Integrins Pathway (106055); Hemostasis Pathway (106028); Integrin AlphaIIb Beta3 Signaling Pathway (106054)

The protein encoded by this gene is the beta component of fibrinogen, a blood-borne glycoprotein comprised of three pairs of nonidentical polypeptide chains. Following vascular injury, fibrinogen is cleaved by thrombin to form fibrin which is the most abundant component of blood clots. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, display vasoconstrictor and chemotactic activities, and are mitogens for several cell types. Mutations in this gene lead to several disorders, including afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia and thrombotic tendency. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2014]

FGB: Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. Defects in FGB are a cause of congenital afibrinogenemia (CAFBN). This rare autosomal recessive disorder is characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Patients with congenital fibrinogen abnormalities can manifest different clinical pictures. Some cases are clinically silent, some show a tendency toward bleeding and some show a predisposition for thrombosis with or without bleeding. Protein type: Cell surface; Secreted; Adaptor/scaffold; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 4q28. Cellular Component: extracellular space; cell surface; fibrinogen complex; plasma membrane; extracellular region; cell cortex; vesicle; external side of plasma membrane. Molecular Function: protein binding, bridging; protein binding; chaperone binding; cell adhesion molecule binding; structural molecule activity; receptor binding. Biological Process: protein polymerization; platelet activation; extracellular matrix organization and biogenesis; cellular protein complex assembly; platelet degranulation; positive regulation of heterotypic cell-cell adhesion; positive regulation of protein secretion; cell-matrix adhesion; positive regulation of vasoconstriction; innate immune response; signal transduction; blood coagulation; response to calcium ion; positive regulation of exocytosis. Disease: Afibrinogenemia, Congenital; Dysfibrinogenemia, Congenital

48-Strip-Wells-(Competitive)

470 USD

48-Strip-Wells-(Sandwich)

470

96-Strip-Wells-(Competitive)

675

96-Strip-Wells-(Sandwich)

675